- The CANSCAN study has registered 120 patients with chronic kidney disease using the VXWAVE ™ imaging system sought and semi-autonomous
- The vxwave ultrasonic imaging system potentially provides important information on vascular access, to possibly activate the creation and previous use of the AV fistula
- Results to present at the annual meeting of the American Society of Nephrology (ASN) in November
Sydney And San Antonio,, July 30, 2025 / Prnewswire / – VexevA company of medical devices based in Australia advances new generation vascular imaging, and US Care Renala leading dialysis supplier in the center and the house The United Statesannounced today the success of registration in the clinical trial of CANSCAN (NCT06691672). The first multicenter feasibility study in its kind has included 120 patients with chronic kidney disease to assess the use of semi-autonomous ultrasonic scanning using the Ultrasore VXWAVE imaging system for the mapping of arteriovenous fistula (AV) in dialysis clinics.
“The VXWAVE ultrasound system can eliminate one of the largest obstacles to the creation of vascular access. Patients could have a vascular cartography carried out in their dialysis establishment, allowing a more effective means of obtaining a permanent vascular access point,” commented Varshi Broumand, MD, MHA, Face, Fasn, interventional nephrologist at the South Texas Renal Group. “The realization of ultrasound analyzes during the clinic visit would make fistula map more practical and timely and would avoid sending patients to additional imaging meetings.”
An AV fistula is a connection established between an artery and a vein, generally in the arm, to create an access point for patients requiring dialysis. This allows blood to flow quickly and easily during treatment, which helps the body to eliminate toxins more effectively. The vxwave ultrasonic imaging system is a robotic ultrasound system specifically designed for the vascular imaging of the upper limbs – integrating advanced robotics, automatic learning and ultrasonic signal processing to create a 3D vascular model and a detailed ratio that potentially provides vascular access points – all at the care point.
“Validation of this concept is the first step towards a future where intelligent machines can perform high -precision medical imaging without human hand on the probe. The potential of a robotic system guided by AI, offering real clinical value – it is no longer science fiction,” said Shannon ThomasMD, chief doctor, vexev. “Real excitement begins when it can change its life, not just the results of the laboratory. It is a huge step forward in our mission to improve the lives of millions of people in the world living with a terminal kidney disease.”
“American kidney care has undertaken to provide innovative treatments that meet the most critical needs of people living with kidney disease,” said Geoffrey A. BlockMD, FASN, assistant doctor and main vice-president, clinical research and medicine, American kidney care. “The CANSCAN test of the VXWAVE Ultrasonic imaging system opens the possibility of integrating semi-autonomous ultrasonic imaging into our workflow and to improve patient results, allowing patients to receive vital permanent vascular access placed in the optimal location, as quickly as possible.”
About Vexev
Vexev is an Australian startup of the Med-Tech founded in 2018 by the DRS. John Carroll And Eamonn collème – New South Wales University (Unsw) Graduates PHD in the dynamics of vascular fluid and computer imagery. Vexev’s mission is to improve lives by developing the next generation of vascular imaging solutions. Visit Vexev.com To find out more.
About us renal care
Us Renal Care, the fastest growth dialysis supplier in the country is associated with nephrologists in 32 states in the United States to take care of more than 36,000 people living with kidney disease. Since 2000, American kidney care has been a leader in clinical quality, innovation and operational excellence – offering the best experience and best results for our patients. Visit Usrenalcare.com To find out more.
Photo – https://mma.prnewswire.com/media/2738051/vexev_usrenal_canscan.jpg
Logo – https://mma.prnewswire.com/media/2738052/vexev_logo.jpg
Show the original content:https://www.prnewswire.com/apac/news-releases/vexev-and-us-renal-care-complete-enrollment-in-groundbingin G-Trial-Evaluating-Use-Of-Robotic-Utrasound-Scanning-For-Av-Fistula-Mapping-Dialsisclinics-302514541.html
Source Vexev
